

Supporting Information

Synthesis and Preclinical Evaluation of 22-[¹⁸F]Fluorodocosahexaenoic Acid as a Positron Emission Tomography Probe for Monitoring Brain Docosahexaenoic Acid Uptake Kinetics

Marlon Vincent V. Duro,^{1,*} Juno Van Valkenburgh,^{1,*} Diana E. Ingles,² Jenny Tran,² Zhiheng Cai,² Brandon Ebright,³ Shaowei Wang,² Bilal E. Kerman,² Jasmin Galvan,² Sung Hee Hwang,⁴ Naomi S. Sta Maria,⁵ Francesca Zanderigo,^{6,7} Etienne Croteau,⁸ Stephen C. Cunnane,⁹ Stanley I. Rapoport,¹⁰ Stan G. Louie,³ Russell E. Jacobs,⁵ Hussein N. Yassine,^{2,**} Kai Chen^{1,**}

¹Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States

²Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States

³Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, United States

⁴Department of Entomology and Nematology and UC Davis Comprehensive Cancer Center, University of California, Davis, CA 95616, United States

⁵Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States

⁶Department of Psychiatry, Columbia University, New York, NY 10032, United States

⁷Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, NY 10032, United States

⁸Sherbrooke Center for Molecular Imaging, University of Sherbrooke Sherbrooke, QC, J1H 4C4, Canada

⁹Research Center on Aging, Department of Medicine, University of Sherbrooke, Sherbrooke, QC, J1H 4C4, Canada

¹⁰National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, United States

* Equal contributions

**Co-senior authors with equal contributions

Correspondence:

Hussein N. Yassine, hyassine@usc.edu

Kai Chen, chenkai@med.usc.edu

TABLE OF CONTENTS

General Chemistry	3
HPLC Methods.....	4
Method A (Analytical HPLC)	4
Method B (Semi-preparative HPLC).....	4
Method C (Semi-preparative HPLC).....	4
Synthetic Procedures	5
Methyl 9-Hydroxynona-4,7-diynoate (1).....	5
Methyl 9-Bromonona-4,7-diynoate (2)	5
Methyl 12-Hydroxydodeca-4,7,10-triynoate (3)	6
Methyl 12-Bromododeca-4,7,10-triynoate (4)	6
6-(Trimethylsilyl)hexa-2,5-diyne-1-ol (5)	7
6-(Trimethylsilyl)hexa-2,5-diyne-1-yl 4-methylbenzenesulfonate (6)	7
10-(Trimethylsilyl)deca-3,6,9-triyn-1-ol (7).....	8
Deca-3,6,9-triyn-1-ol (8)	8
Methyl (4Z,7Z,10Z,13Z,16Z,19Z)-22-(Tosyloxy)docosa-4,7,10,13,16,19-hexaenoate (11)	9
Methyl 22-Hydroxydocosa-4,7,10,13,16,19-hexaynoate (9).....	10
Methyl (4Z,7Z,10Z,13Z,16Z,19Z)-22-Hydroxydocosa-4,7,10,13,16,19-hexaenoate (10)	11
Methyl (4Z,7Z,10Z,13Z,16Z,19Z)-22-Fluorodocosa-4,7,10,13,16,19-hexaenoate (13).....	11
Methyl (4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19,21-heptaenoate (12)	11
(4Z,7Z,10Z,13Z,16Z,19Z)-22-Fluorodocosa-4,7,10,13,16,19-hexaenoic acid (22-FDHA)	12
NMR Spectra	13
<i>Ex Vivo</i> LC-MS Analysis of 22-FDHA.....	25
PET Imaging of 22- ¹⁸ F]FDHA in Normal Nude Mice	30
REFERENCES.....	30

General Chemistry

All reagents and solvents were obtained from various commercial sources and used without further purification unless otherwise noted. All reactions were performed under nitrogen gas unless otherwise mentioned. Thin-layer chromatography (TLC) was performed on precoated silica gel 60 Å plates with UV 254 indicator and visualized with either UV light or a KMnO₄ stain. Automated flash chromatography was performed using a Teledyne ISCO CombiFlash Rf 200 automatic chromatography system with RediSep prepacked gel cartridges. Nuclear magnetic resonance (NMR) spectra were recorded on a 400 MHz Oxford NMR AS400, a 400 MHz Varian Mercury, or a 500 MHz Varian VNMRS NMR spectrometer. Proton and ¹³C NMR chemical shifts are reported in ppm (δ) downfield from TMS using internal TMS or residual protonated solvent as reference (CHCl₃: 7.26 ppm for ¹H and 77.16 ppm for ¹³C). Fluorine-19 NMR chemical shifts are reported in ppm downfield from CFCl₃ using the deuterium lock channel as a reference. NMR data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, dt = triplet of doublets, dq = quartet of doublets, tt = triplet of triplets, m = multiplet), coupling constant (*J* in Hz), and integration. Low-resolution mass spectra were obtained on an MSQ Plus single quadrupole mass spectrometer in positive mode with an electrospray ionization (ESI) ion source. High-resolution mass spectra were obtained on a Thermo Fisher Q-Exactive Orbitrap system in positive mode with an ESI ion source.

HPLC Methods

Method A (Analytical HPLC)

Analytical reversed-phase high-performance liquid chromatography (HPLC) was carried out using a Thermo Scientific UltiMate 3000 HPLC system with a Phenomenex Luna C18(2) reversed-phase column (5 μm , 250 mm \times 4.6 mm). The UV absorbance was recorded at 214 and 250 nm. Radioactivity was recorded using a Model 105 radio-detector (Carroll & Ramsey Associates, Berkeley, CA). The mobile phases were A, H₂O with 0.1% TFA and B, MeCN with 0.1% TFA. The gradient was as follows: 0–1 min, 100% A; 1–11 min, 0–100% B; 11–16.5 min, 100% B; 16.5–17.5 min, 100–0% B; and 17.5–20 min, 100% A, at a flow rate of 1 mL/min.

Method B (Semi-preparative HPLC)


Purification of the fluorination precursor **11** was conducted on a Thermo Scientific UltiMate 3000 HPLC system with a Phenomenex Luna C18(2) reversed-phase column (5 μm , 250 mm \times 10 mm). The UV absorbance was recorded at 214 and 254 nm. The mobile phases were A, H₂O and B, MeCN. The gradient was as follows: 0–3 min, 100% A; 3–20 min, 0–100% B; 20–27.5 min, 100% B; 27.5–30 min, 100–0% B; and 30–33 min, 100% A, at a flow rate of 3 mL/min.

Method C (Semi-preparative HPLC)

Purification of 22-[¹⁸F]FDHA was performed on a Knauer HPLC system with an Azura P 6.1L HPG pump and BlueShadow 40D UV/VIS detector with a Phenomenex Luna C18(2) reversed-phase column (5 μm , 250 mm \times 10 mm). The UV absorbance was recorded at 254 nm. Radioactivity was recorded using a Model 101 radio-detector (Carroll & Ramsey Associates, Berkeley, CA). The mobile phases were A, H₂O and B, MeCN. The gradient was as follows: 0–3 min, 100% A; 3–20 min, 0–100% B; 20–27.5 min, 100% B; 27.5–30 min, 100–0% B; and 30–33 min, 100% A, at a flow rate of 3 mL/min.

Synthetic Procedures


Methyl 9-Hydroxynona-4,7-diynoate (**1**)



A procedure from the literature¹ was modified as follows: to a solution of methyl 4-pentynoate (617.2 mg, 1.2 equiv) in anhyd. *N,N*-dimethylformamide (DMF, 10 mL) was added NaI (900.1 mg, 1.2 equiv), CuI (1.14 g, 1.2 equiv), and Cs₂CO₃ (2.45 g, 1.5 equiv) with rapid stirring. To the mixture was then added a solution of 4-chlorobutyn-1-ol (523.0 mg,) in anhyd. DMF (2 mL). Stirring was continued overnight, then the mixture was diluted with ethyl acetate (EtOAc, 40 mL). To this was then added a mixture of saturated aq. NH₄Cl (40 mL) and saturated aq. Na₂S₂O₃ (10 mL). The biphasic mixture was separated, and the aqueous layer was then extracted with EtOAc (2 × 25 mL) and the combined organic layers were washed with water (20 mL), then saturated aq. NaCl (brine, 10 mL). The organic solution was then dried over anhyd. MgSO₄ and evaporated under reduced pressure. The residue was loaded onto silica gel and purified by flash chromatography (12 g silica, 0–50% EtOAc in hexanes) to obtain diyne **1** as a yellow oil (746.6 mg, 83% yield). Spectral data agree with those in the literature¹:

TLC: *R*_f = 0.41 (1:1 EtOAc/hexanes). ¹H NMR (500 MHz, CDCl₃): δ 4.24 (t, *J* = 2.2 Hz, 2H), 3.69 (s, 3H), 3.16 (p, *J* = 2.3 Hz, 2H), 2.57 – 2.42 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 172.61, 80.48, 79.09, 78.71, 74.48, 51.94, 51.31, 33.44, 14.72, 9.95.

Methyl 9-Bromonona-4,7-diynoate (**2**)




A procedure from the literature¹ was modified as follows: to a solution of **1** (519.4 mg, 2.88 mmol) and CBr₄ (1.44 mg, 1.5 equiv) in anhyd. dichloromethane (DCM, 7.5 mL), cooled in an ice-water bath, was added a solution of triphenylphosphine (PPh₃, 1.14 mg, 1.5 equiv) in anhyd. DCM (2.5 mL) with stirring. After 1.5 h, the solution was evaporated under reduced pressure then the residue was loaded onto silica gel. After flash chromatography (12 g silica, 0–20% EtOAc in hexanes),

bromide **2** was obtained as a yellow oil (559.4 mg, 80% yield). Spectral data agree with those in the literature¹:

TLC: $R_f = 0.73$ (1:1 EtOAc/hexanes). ¹H NMR (400 MHz, CDCl₃): δ 3.90 (t, $J = 2.3$ Hz, 2H), 3.70 (s, 3H), 3.20 (p, $J = 2.4$ Hz, 2H), 2.59 – 2.41 (m, 4H). ¹³C NMR (100 MHz, CDCl₃): δ 172.56, 81.78, 79.36, 75.55, 73.90, 51.97, 33.39, 14.92, 14.73, 10.23.


Methyl 12-Hydroxydodeca-4,7,10-triynoate (**3**)



Following a similar procedure for the synthesis of **1**, the reaction of compound **2** (559.4 mg, 2.30 mmol), propargyl alcohol (195 mg, 2 equiv), CuI (658 mg, 1.2 equiv), NaI (520 mg, 1.2 equiv), and Cs₂CO₃ (1.50 g, 1.5 equiv) in DMF (8 mL), followed by aqueous work-up and flash chromatography (12 g silica, 0–50% EtOAc in hexanes) afforded triyne **3** as a yellow oil (327.7 mg, 65% yield). Spectral data agree with those in the literature¹:

TLC $R_f = 0.42$ (1:1 EtOAc/hexanes). ¹H NMR (500 MHz, CDCl₃): δ 4.25 (t, $J = 2.1$ Hz, 2H), 3.69 (s, 3H), 3.19 (p, $J = 2.3$ Hz, 2H), 3.11 (p, $J = 2.3$ Hz, 2H), 2.55 – 2.44 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 172.63, 80.09, 78.93, 78.89, 75.27, 74.69, 74.02, 51.94, 51.32, 33.48, 14.75, 9.99, 9.86. MS (ESI) m/z : $[M+H]^+$ Calcd for C₁₃H₁₅O₃ 219.1; Found. 219.2.

Methyl 12-Bromododeca-4,7,10-triynoate (**4**)




Following a similar procedure for the synthesis of **2**, the reaction of compound **3** (327.7 mg, 1.5 mmol), CBr₄ (745.1 mg, 1.5 equiv), and triphenylphosphine (707.3 mg, 1.5 equiv) in DCM (11 mL), followed by flash chromatography (4 g silica, 0–20% EtOAc in hexanes) afforded the bromide **4** as a yellow oil (259.1 mg, 61% yield). Spectral data agree with those in the literature¹:

TLC: $R_f = 0.75$ (1:1 hexanes/EtOAc). ¹H NMR (400 MHz, CDCl₃): δ 3.90 (t, $J = 2.3$ Hz, 2H), 3.70 (s, 3H), 3.22 (p, $J = 2.3$ Hz, 2H), 3.12 (p, $J = 2.3$ Hz, 2H), 2.57 – 2.42 (m, 4H). ¹³C NMR (100

MHz, CDCl₃): δ 172.57, 81.37, 78.99, 75.75, 75.51, 74.59, 73.51, 51.95, 33.47, 14.83, 14.76, 10.27, 9.89


6-(Trimethylsilyl)hexa-2,5-diyne-1-ol (**5**)



Following a similar procedure for the synthesis of **1**, 3-bromo-1-(trimethylsilyl)-1-propyne (1.05 g, 3 mmol), propargyl alcohol (257.6 mg, 1.5 equiv), CuI (693.4 g, 1.2 equiv), NaI (546 mg, 1.2 equiv), and Cs₂CO₃ (1.47 g, 1.5 equiv) in DMF (9 mL), followed by aqueous work-up and flash chromatography (12 g silica, 0–40% EtOAc in hexanes) afforded diyne **5** as a light-yellow oil (468.3 mg, 94% yield). Spectral data agree with those in the literature¹:

TLC: R_f = 0.63 (1:1 EtOAc/hexanes), R_f = 0.29 (1:4 EtOAc/hexanes). ¹H NMR (400 MHz, CDCl₃): δ 4.26 (t, J = 2.2 Hz, 2H), 3.25 (t, J = 2.2 Hz, 2H), 0.15 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 99.47, 85.61, 79.81, 78.94, 51.36, 11.08, -0.01.


6-(Trimethylsilyl)hexa-2,5-diyne-1-yl 4-methylbenzenesulfonate (**6**)



To a solution of **5** (410.0 mg, 2.47 mmol) in anhyd. DCM (8 mL), cooled in an ice-water bath, was added pyridine (280 μ L, 1.4 equiv) and *p*-toluenesulfonic anhydride (freshly recrystallized from hot EtOAc, 1.04 g, 1.3 equiv). The mixture was slowly warmed to room temperature. After 1 h, the mixture was partitioned between DCM (15 mL) and saturated aq. NH₄Cl (15 mL). The aqueous layer was extracted with DCM (2 \times 10 mL) and the pooled organic solutions were washed with brine. The organic solution was dried over anhyd. Na₂SO₄, then evaporated under reduced pressure. The residue was loaded onto silica gel and after flash chromatography (12 g silica, 0–20% EtOAc in hexanes), tosylate **6** was obtained as a yellow oil (471.7 mg, 60% yield). Spectral data agree with those in the literature¹:

TLC: R_f = 0.43 (1:4 EtOAc/hexanes), R_f = 0.74 (1:1 EtOAc/hexanes). ¹H NMR (400 MHz, CDCl₃): δ 7.82 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 4.70 (t, J = 2.2 Hz, 2H), 3.11 (t, J = 2.2 Hz, 3H), 2.46 (s, 3H), 0.16 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 145.15, 133.33, 129.94, 128.31, 98.27, 86.06, 83.60, 72.61, 58.32, 21.82, 11.08, -0.03.


10-(Trimethylsilyl)deca-3,6,9-triyn-1-ol (**7**)



Following a similar procedure for the synthesis of **1**, the reaction of compound **6** (1.25 g, 3.9 mmol), 3-butyn-1-ol (361.6 mg, 1.5 equiv), CuI (898 mg, 1.2 equiv), NaI (704 mg, 1.2 equiv), and Cs₂CO₃ (1.91 g, 1.5 equiv) in DMF (12 mL), followed by aqueous work-up and flash chromatography (12 g silica, 0–30% EtOAc in hexanes) afforded triyne **7** as a yellow oil (409.9 mg, 48% yield). Spectral data agree with those in the literature¹:

TLC: $R_f = 0.57$ (1:1 EtOAc/hexanes), $R_f = 0.19$ (1:4 EtOAc/hexanes). ¹H NMR (400 MHz, CDCl₃): δ 3.70 (t, $J = 6.2$ Hz, 2H), 3.20 (t, $J = 2.4$ Hz, 2H), 3.16 (p, $J = 2.4$ Hz, 2H), 2.44 (tt, $J = 6.2, 2.4$ Hz, 2H), 1.77 (s, 1H), 0.16 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 99.90, 85.35, 77.39, 76.24, 75.06, 74.19, 61.23, 23.24, 11.05, 10.00, 0.04.


Deca-3,6,9-triyn-1-ol (**8**)



A procedure from the literature¹ was modified as follows: compound **7** (409.9 mg, 1.88 mmol) was dissolved in anhyd. tetrahydrofuran (THF, 10 mL) and cooled in an ice-water bath. Acetic acid (65 μ L, 0.6 equiv) was added to a 1 M solution of tetrabutylammonium fluoride (TBAF) in THF (2.25 mL, 1.2 equiv) and this mixture was then added dropwise with stirring over 5 min to the cooled THF solution of **7**. The resulting brown solution was stirred for 1 h, and then partitioned between diethyl ether (40 mL) and cold water (40 mL). The aqueous layer was further extracted with diethyl ether (3 \times 15 mL) and the pooled organic layers were washed with water (20 mL) and brine (20 mL). The organic solution was dried over anhyd. Na₂SO₄ and evaporated under reduced pressure. The residue was loaded onto silica gel and after flash chromatography (4 g silica, 0–40% EtOAc in hexanes), desilylated triyne **8** was obtained as a light-yellow oil (229.5 mg, 84% yield). Spectral data agree with those in the literature¹:


TLC: $R_f = 0.51$ (1:1 EtOAc/hexanes), $R_f = 0.14$ (1:4 EtOAc/hexanes). ¹H NMR (400 MHz, CDCl₃): δ 3.69 (t, $J = 6.3$ Hz, 2H), 3.18 – 3.11 (m, 4H), 2.43 (tt, $J = 6.3, 2.3$ Hz, 2H), 2.06 (t, $J = 2.6$ Hz,

Methyl (4Z,7Z,10Z,13Z,16Z,19Z)-22-Hydroxydocosa-4,7,10,13,16,19-hexaenoate (10)



TLC: $R_f = 0.69$ (1:1 EtOAc/hexanes), $R_f = 0.19$ (1:4 EtOAc/hexanes). Analytical HPLC (Method A): $t_r = 14.79$ min. MS (ESI) m/z : $[M+H]^+$ Calcd for $C_{23}H_{23}O_3$ 359.3; Found 359.3.


Methyl (4Z,7Z,10Z,13Z,16Z,19Z)-22-Fluorodocosa-4,7,10,13,16,19-hexaenoate (13)



A procedure from the literature² was modified as follows: to a solution of **11** (10.7 mg) in anhyd. THF (1.5 mL), cooled in an ice-water bath, was added 1 M TBAF in THF (87 μ L, 4.2 equiv). The resulting orange solution was slowly warmed to room temperature with stirring overnight. The solution was evaporated under reduced pressure and the residue was taken up in DCM (5 mL). The solution was washed with water (1 mL) and then brine (1 mL). After drying the solution over anhyd. Na_2SO_4 , the solvent was evaporated under reduced pressure and the residue was loaded onto silica gel. After flash chromatography (4 g silica, 0–5% EtOAc in hexanes), two products were isolated as colorless oils: an elimination product **12** (2.2 mg, 29% yield) and the intended substitution product **13** (2.1 mg, 29% yield):


TLC: $R_f = 0.39$ (1:9 EtOAc/hexanes), $R_f = 0.22$ (1:19 EtOAc/hexanes). Analytical HPLC (Method A): $t_r = 15.49$ min. 1H NMR (400 MHz, $CDCl_3$): δ 5.58 – 5.29 (m, 12H), 4.43 (dt, $^2J_{FH} = 47.1$ Hz, $^3J_{HH} = 6.5$ Hz, 2H), 3.67 (s, 3H), 2.92 – 2.72 (m, 10H), 2.49 (dq, $^3J_{FH} = 22.3$ Hz, $^3J_{HH} = 6.8$ Hz, 2H), 2.42 – 2.33 (m, 4H). ^{19}F NMR (376 MHz, $CDCl_3$): δ –216.81 (tt, $^2J_{HF} = 47.0$ Hz, $^3J_{HF} = 23.4$ Hz).

Methyl (4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19,21-heptaenoate (12)



TLC: $R_f = 0.46$ (1:9 EtOAc/hexanes), $R_f = 0.28$ (1:19 EtOAc/hexanes). Analytical HPLC (Method A): $t_r = 16.29$ min. 1H NMR (400 MHz, $CDCl_3$): δ 6.66 (dt, $J = 16.9, 10.6$ Hz, 1H), 6.02 (t, $J = 10.9$ Hz, 1H), 5.48 – 5.32 (m, 11H), 5.21 (d, $J = 16.8$ Hz, 1H), 5.12 (d, $J = 10.1$ Hz, 1H), 3.67 (s, 3H), 2.97 (t, $J = 6.8$ Hz, 2H), 2.91 – 2.80 (m, 8H), 2.44 – 2.33 (m, 4H).

(4Z,7Z,10Z,13Z,16Z,19Z)-22-Fluorodocosa-4,7,10,13,16,19-hexaenoic acid (22-FDHA)




A procedure from the literature² was adapted as follows: to a solution of the methyl ester **13** (2.1 mg) in THF (0.85 mL) was added a solution of LiOH (1.1 mg, 8 equiv) in water (0.15 mL). After stirring overnight at room temperature, the mixture was diluted with water (1.0 mL), then the pH was adjusted to around 2 with 0.1 M aq. H₂SO₄. The aqueous mixture was then extracted with DCM (3 × 1 mL) and the pooled organic solutions were washed with brine (1 mL), then dried over anhyd. MgSO₄. The solution was evaporated under reduced pressure and the residue was loaded onto silica gel. After flash chromatography (4 g silica, 0–20 % EtOAc in hexanes), 22-FDHA in its free acid form was obtained as a colorless oil (1.9 mg, 94%, yield):

TLC: $R_f = 0.13$ (1:4 EtOAc/hexanes). Analytical HPLC (Method A): $t_r = 14.47$ min. ¹H NMR (500 MHz, CDCl₃): δ 5.63 – 5.25 (m, 12H), 4.43 (dt, ² $J_{FH} = 47.2$ Hz, ³ $J_{HH} = 6.5$ Hz, 2H), 2.92 – 2.71 (m, 10H), 2.49 (dq, ³ $J_{FH} = 23.0$ Hz, ³ $J_{HH} = 6.8$ Hz, 2H), 2.42 – 2.37 (m, 4H). ¹⁹F NMR (470 MHz, CDCl₃): δ –216.75 (tt, ² $J_{HF} = 47.0$ Hz, ³ $J_{HF} = 23.4$ Hz). ¹³C NMR (100 MHz, CDCl₃): δ 177.70, 131.25, 129.66, 128.53, 128.41, 128.37, 128.32, 128.30, 128.23, 128.17, 127.99, 127.78, 124.08 (d, ³ $J_{FC} = 7.3$ Hz), 83.32 (d, ¹ $J_{FC} = 167.9$ Hz), 33.96, 28.81 (d, ² $J_{FC} = 20.7$ Hz), 25.86, 25.79, 25.78, 25.77, 25.73, 22.72. HRMS (ESI/QTOF) m/z : [M+H]⁺ Calcd for C₂₂H₃₁FO₂ 347.2381; Found 347.2371.


NMR Spectra

PROTON_01
cdcl3, 499.77 MHz




^1H NMR (CDCl_3 , 500 MHz) spectrum of **1**

CARBON_01
cdcl3, 125.68 MHz




$^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) spectrum of **1**

PROTON_01
cdcl3, 399.80 MHz




^1H NMR (CDCl_3 , 400 MHz) spectrum of **2**

CARBON_01
cdcl3, 100.54 MHz




$^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) spectrum of **2**

PROTON_01
cdcl3, 499.77 MHz




^1H NMR (CDCl_3 , 500 MHz) spectrum of **3**

CARBON_01
cdcl3, 125.68 MHz




$^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 125 MHz) spectrum of **3**

PROTON_01
cdcl3, 400.07 MHz




¹H NMR (CDCl₃, 400 MHz) spectrum of **4**

CARBON_01
cdcl3, 100.61 MHz




¹³C{¹H} NMR (CDCl₃, 100 MHz) spectrum of **4**

PROTON_01
cdcl3, 399.80 MHz




^1H NMR (CDCl_3 , 400 MHz) spectrum of **5**

CARBON_01
cdcl3, 100.54 MHz




$^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) spectrum of **5**

PROTON_01
cdcl3, 399.80 MHz




^1H NMR (CDCl_3 , 400 MHz) spectrum of **6**

CARBON_01
cdcl3, 100.62 MHz




$^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) spectrum of **6**

PROTON_01
cdcl3, 400.07 MHz




^1H NMR (CDCl_3 , 400 MHz) spectrum of **7**

CARBON_01
cdcl3, 100.61 MHz




$^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) spectrum of **7**

PROTON_01
cdcl3, 400.10 MHz




¹H NMR (CDCl₃, 400 MHz) spectrum of **8**

CARBON_01
cdcl3, 100.62 MHz




¹³C{¹H} NMR (CDCl₃, 100 MHz) spectrum of **8**

PROTON_01
cdcl3, 399.80 MHz




¹H NMR (CDCl₃, 400 MHz) spectrum of **12**

PROTON_03
cdcl3, 399.80 MHz




¹H NMR (CDCl₃, 400 MHz) spectrum of **13**

FLUORINE_03
cdcl3, 376.10 MHz




^{19}F NMR (CDCl_3 , 376 MHz) spectrum of **13**

PROTON_03
cdcl3, 499.76 MHz




^1H NMR (CDCl_3 , 500 MHz) spectrum of **22-FDHA**

FLUORINE_01
cdcl3, 470.15 MHz



^{19}F NMR (CDCl_3 , 470 MHz) spectrum of 22-FDHA



$^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 100 MHz) spectrum of 22-FDHA.

Ex Vivo LC-MS Analysis of 22-FDHA

Probe Injection and Tissue Extraction

A solution of 22-FDHA in acetonitrile was dried in a glass vial under a stream of filtered dry N₂ gas, and then under vacuum. The residue was formulated in injection buffer to a concentration of 10 ng/mL. A female mouse was anesthetized with isoflurane, and then 1 µg of 22-FDHA was injected into the tail vein. The mouse was kept under maintenance anesthesia for 30 min after which it was dissected and euthanized by cardiac puncture. Approximately 500 µL of blood was extracted from the heart and transferred to an EDTA-coated microcentrifuge tube. After blood collection, the mouse was immediately perfused with cold PBS then the liver and brain were extracted. Tissues, including isolated plasma, brain, and liver, were stored at -80 °C until processing. Following the same procedure, another mouse was injected with 500 ng 22-[¹⁸F]FDHA, and the tissues were extracted at 30 min p.i.

Plasma and Brain 22-FDHA Extraction

22-FDHA was extracted from mouse plasma (100 µL) and brain tissue (~250 mg) and then quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM). Prior to extraction, mouse brains were cut in half through the midsagittal plane, and the left brain was used for analysis. Standard curve samples were prepared by spiking 3X stripped C57BL mouse plasma (BioIVT) with varied concentrations of synthetic 22-FDHA. To extract 22-FDHA and prevent lipid peroxidation, methanol (MeOH) containing 0.05% butylated hydroxytoluene and triphenylphosphine was added to plasma samples (200 µL) and brain tissues (500 µL). 50 µL *d5*-DHA (50 ng/mL, Cayman) was added to each sample and used as the internal standard for quantification. To facilitate the extraction of 22-FDHA from plasma, samples were vortexed for 10 seconds and kept cool in ice for 10 min while brain tissues were homogenized. Brain samples were homogenized completely using a pre-cooled TissueLyser (Qiagen) at 30 Hz at 1.5-min intervals. Subsequently, plasma and brain samples were centrifuged at 10,000×g for 10 min at 4 °C. The supernatant was collected from each sample and diluted with water to obtain 10% MeOH solutions. Each sample was then subjected to solid phase extraction using Strata X 33µm Polymeric Reverse Phase cartridges (Phenomenex). Cartridges were pre-conditioned with MeOH (1 mL) followed by water (1 mL) before the diluted samples were eluted

through and then washed with water (1 mL). 22-FDHA and the internal standard were eluted using 700 μ L MeOH, which was then evaporated to dryness under a steady stream of filtered dry N₂ gas. The dried residues were reconstituted with 50% aq. MeOH (50 μ L) and centrifuged to remove any undissolved debris before transferring it to UV-resistant glass vials for LC-MS/MS analysis.


LC-MS/MS Analysis

22-FDHA and *d*₅-DHA were separated and quantified in an Agilent 1290 UPLC system coupled to a Sciex QTRAP API6500+ system using ESI in negative ion mode. For adequate separation, a Poroshell 120 EC-C₁₈ column (2.7 μ m, 4.6 \times 100 mm, Agilent) was used with the mobile phases: A, 0.01% formic acid in H₂O; and B, 0.01% formic acid in MeOH. The gradient was as follows: 0–0.1 min, 20–50% B; 0.1–2 min, 50% B; 2–11 min, 50–80% B; 11–14.5 min, 80% B; 14.5–14.6 min, 80–98% B; 14.6–20 min, 98% B; 20–20.1 min, 98–20% B; 20.1–23 min, 20% B. An injection volume of 20 μ L was used and the flow rate was held at 0.5 mL/min while the column temperature was set to 40 °C. Both 22-FDHA and *d*₅-DHA were detected using unique MRM signatures (Supplementary Table 1) and data analysis and quantification were performed using Skyline 23.1.³


Supplementary Table 1. LC-MS/MS Assay MRM Signatures

Compound	Q1 (<i>m/z</i>)	Q3 (<i>m/z</i>)	RT (min)	DP (V)	CE (V)	CXP (V)	Internal Standard
<i>d</i> ₅ -DHA	332.3	288.3	18.2	-60	-16	-14	N/A
22-FDHA	345.1	325.3	17.5	-80	-13	-14	<i>d</i> ₅ -DHA


d_5 -DHA



DHA




22-FDHA




Supplementary Figure S1. Extracted ion chromatograms for d_5 -DHA (internal standard), DHA, and 22-FDHA of the brain extract of a mouse injected with 1 μ g of 22-FDHA.


d_5 -DHA



DHA




22-FDHA




Supplementary Figure S2. Extracted ion chromatograms for d_5 -DHA (internal standard), DHA, and 22-FDHA of the plasma extract of a mouse injected with 1 μ g of 22-FDHA.


d_5 -DHA



DHA




22-FDHA



Supplementary Figure S3. Extracted ion chromatograms for d_5 -DHA (internal standard), DHA, and 22-FDHA of the liver extract of a mouse injected with 1 μ g of 22-FDHA.

PET Imaging of 22-[¹⁸F]FDHA in Normal Nude Mice



Supplementary Figure S4. PET images of a representative mouse after the injection of 22-[¹⁸F]FDHA at different time points. Normal nude mice ($n = 3$) were injected with a bolus of 22-[¹⁸F]FDHA (9–11 MBq) via the tail vein. PET images were acquired for 5 min at 15, 30, and 60 min p.i.

REFERENCES

- (1) Hwang, S. H.; Wagner, K.; Xu, J.; Yang, J.; Li, X.; Cao, Z.; Morisseau, C.; Lee, K. S.; Hammock, B. D. Chemical Synthesis and Biological Evaluation of Omega-Hydroxy Polyunsaturated Fatty Acids. *Bioorg. Med. Chem. Lett.* **2017**, *27* (3), 620–625.
- (2) Van Valkenburgh, J.; Duro, M. V. V.; Burnham, E.; Chen, Q.; Wang, S.; Tran, J.; Kerman, B. E.; Hwang, S. H.; Liu, X.; Sta Maria, N. S.; Zanderigo, F.; Croteau, E.; Rapoport, S. I.; Cunnane, S. C.; Jacobs, R. E.; Yassine, H. N.; Chen, K. Radiosynthesis of 20-[¹⁸F]Fluoroarachidonic Acid for PET-MR Imaging: Biological Evaluation in ApoE4-TR Mice. *Prostaglandins Leukot. Essent. Fatty Acids* **2022**, *186*, 102510.
- (3) Adams, K. J.; Pratt, B.; Bose, N.; Dubois, L. G.; St John-Williams, L.; Perrott, K. M.; Ky, K.; Kapahi, P.; Sharma, V.; MacCoss, M. J.; Moseley, M. A.; Colton, C. A.; MacLean, B. X.; Schilling, B.; Thompson, J. W.; Alzheimer's Disease Metabolomics, C. Skyline for Small Molecules: A Unifying Software Package for Quantitative Metabolomics. *J Proteome Res* **2020**, *19* (4), 1447–1458.